Solutions for Gluten Induced Disorders

AMYRA Biotech AG

AMYRA Biotech AG is a Swiss joint stock company founded by serial entrepreneurs in the life sciences sector.

How is AMYRA fighting celiac disease and gluten sensitivity?

AMYRA is developing therapeutic product applications for the treatment of celiac disease and gluten sensitivity, which represent major public health issues. Both conditions are triggered by the ingestion of gluten, which is ubiquitously present in the Western diet and thus almost impossible to avoid.

AMY01 & AMY02

AMYRA‘s two lead product candidates are AMY01 for the treatment of celiac disease and AMY02 for the treatment of gluten sensitivity. Each product comprises of two proprietary, synergistically acting, recombinant enzymes that rapidly and entirely destroy the immunogenic structure of toxic gluten fragments (gliadins) – a phenomenon that has never been shown before. The enzymes are safe, highly effective and stable.

What does it mean for patients?

Celiac patients suffer from extremely discomforting acute symptoms and have a high risk of developing serious long-term complications, including cancer, osteoporosis, arthritis and others. Despite being the most common autoimmune disease worldwide, no effective treatment is available to date to address this vast unmet medical need. Strict, life-long avoidance of gluten is the only available treatment option but is very difficult to achieve in practice.

What does it mean for patients?

Celiac patients suffer from extremely discomforting acute symptoms and have a high risk of developing serious long-term complications, including cancer, osteoporosis, arthritis and others. Despite being the most common autoimmune disease worldwide, no effective treatment is available to date to address this vast unmet medical need. Strict, life-long avoidance of gluten is the only available treatment option but is very difficult to achieve in practice.

What does it mean for patients?

Celiac patients suffer from extremely discomforting acute symptoms and have a high risk of developing serious long-term complications, including cancer, osteoporosis, arthritis and others. Despite being the most common autoimmune disease worldwide, no effective treatment is available to date to address this vast unmet medical need. Strict, life-long avoidance of gluten is the only available treatment option but is very difficult to achieve in practice.

What makes AMYRA unique?

Unique mode-of-action

AMYRA’s enzymes have unprecedented proteolytic activity, no toxicity, high stability and strictly local activity, qualifying as functional cures.

Mitigated development risk

and high probability of clinical, regulatory and commercial success.

AYMRA’s products have the potential to establish a new standard of care and majorly impact the lives of affected people.

What makes AMYRA unique?

Unique mode-of-action

AMYRA’s enzymes have unprecedented proteolytic activity, no toxicity, high stability and strictly local activity, qualifying as functional cures.

Mitigated development risk

and high probability of clinical, regulatory and commercial success.

AYMRA’s products have the potential to establish a new standard of care and majorly impact the lives of affected people.

AMYRA’s Development Pipeline

Discovery

Lead Optimization

Pre-Clinical

Clinical

Indication

AMY01: Celiac Disease

75%

AMY02: Gluten Sensitivity

45%

AMY03: Diagnostic Tool

20%

AMY04: Food Additive

15%

AMYRA’s Development Pipeline

AMYRA’s Development Pipeline

AMY01: Celiac Disease

75%

AMY02: Gluten Sensitivity

45%

AMY03: Diagnostic Tool

20%

AMY04: Food Additive

15%

About Us

Company Management

Board of Directors

Scientific Advisory Board

Contact Us

This website is operated by
AMYRA Biotech AG
Malzgasse 9
CH – 4052 Basel
+41 61 515 07 70

UID CHE-321.956.288 MWST
Managing officer:
Caspar Graf von Moy

amyrablue

This website is operated by
AMYRA Biotech AG
Malzgasse 9
CH – 4052 Basel
+41 61 515 07 70

UID CHE-321.956.288 MWST
Managing officer: Caspar Graf von Moy

Disclaimer

Welcome to AMYRA Biotech AG. By using our website, you are accepting the following:

Copyright and Limitation of Liability

This website and its content are copyrighted by AMYRA Biotech AG. You may use, e.g. download or copy any content form this website for personal use only. Any other use of the content of this website is not permitted.

“Sand-Sailing” image © TZ SPO

“Team” image © alfa27 / Adobe Stock

“Woman Eating” © Martinan / Adobe Stock

“Basel Skyline” © bill_17 / Adobe Stock

This website is for information purposes only and does not contain medical advice. While we are diligently updating our website, we are not bound by the information published and do not guarantee the content to be accurate or up-to-date. AMYRA Biotech AG cannot be held liable for any damage that could arise out of or in connection with the use of this website. AMYRA Biotech AG is particularly not responsible for damage resulting from incorrect, incomplete or outdated information or the loss of data. In case we are linking to other websites, AMYRA Biotech AG is not responsible for such third-party websites. All such limitations are subject to the extent permissible under the applicable law.

Privacy and Personal Data

AMYRA Biotech AG respects your privacy. You can browse this website without providing us with personal data. We may collect, store and process your personal data if you contact us by email. We will use your personal data for administrative purposes and to inform you about our services and products. We will not provide third parties with your personal data for purposes other than those listed.

We use cookies on this website. Cookies are small text files which are downloaded onto your hard disk when you access this website. Cookies allow recognizing your preferences or past actions and assist you with navigation on the website. You may disable the cookies function in your web browser, if you do not want to allow cookies being stored on your computer. With cookies deactivated, not all features of this website may function properly.

Contact us

Drop us a line and we'll get back to you.

Not readable? Change text. captcha txt